Profusa, Inc.

Profusa, Inc., trading under ticker NVAC, filed its annual Form 10-K with the Securities and Exchange Commission on March 31, 2025, covering fiscal year operations as a post-merger public company. Profusa is a biomedical firm focused on implantable biosensor technology that enables continuous physiological monitoring at the tissue level, placing it firmly in the healthcare and medical devices sector. The company achieved its current public status through a SPAC business combination, and the 10-K filing reflects its ongoing reporting obligations as a registered public issuer. For complete filing history, sponsor details, transaction timelines, and real-time analytics on NVAC and the broader SPAC universe, sign up for full data access at SpacDesk.